297 related articles for article (PubMed ID: 30249218)
1. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.
Caroff SN; Mu F; Ayyagari R; Schilling T; Abler V; Carroll B
BMC Psychiatry; 2018 Sep; 18(1):306. PubMed ID: 30249218
[TBL] [Abstract][Full Text] [Related]
2. Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia.
Caroff SN; Mu F; Ayyagari R; Schilling T; Abler V; Carroll B
BMC Psychiatry; 2020 Jul; 20(1):365. PubMed ID: 32652964
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with Schizophrenia.
Zichlin ML; Mu F; Leo S; Ayyagari R
Clin Drug Investig; 2021 Oct; 41(10):853-863. PubMed ID: 34480726
[TBL] [Abstract][Full Text] [Related]
4. The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.
McEvoy J; Park T; Schilling T; Terasawa E; Ayyagari R; Carroll B
Curr Med Res Opin; 2019 Jul; 35(7):1205-1214. PubMed ID: 30638073
[No Abstract] [Full Text] [Related]
5. Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders.
Ayyagari R; Thomason D; Mu F; Philbin M; Carroll B
J Med Econ; 2020 Feb; 23(2):204-212. PubMed ID: 31663802
[No Abstract] [Full Text] [Related]
6. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis.
Patterson-Lomba O; Ayyagari R; Carroll B
BMC Neurol; 2019 Jul; 19(1):174. PubMed ID: 31325958
[TBL] [Abstract][Full Text] [Related]
7. Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States.
Loughlin AM; Lin N; Abler V; Carroll B
PLoS One; 2019; 14(6):e0216044. PubMed ID: 31163035
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
9. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
McGrath JJ; Soares KV
Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
[TBL] [Abstract][Full Text] [Related]
10. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
Soares-Weiser K; Rathbone J
Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
12. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
Seigneurie AS; Sauvanaud F; Limosin F
Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Antipsychotic Dosage in Patients With Tardive Dyskinesia: A Case-Control Study Using the Claims Database of the Corporate Health Insurance Association.
Gouda M; Abe M; Watanabe Y; Kato TA
J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):378-385. PubMed ID: 38829574
[TBL] [Abstract][Full Text] [Related]
14. Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia.
Carroll B; Irwin DE
J Manag Care Spec Pharm; 2019 Jul; 25(7):810-816. PubMed ID: 31232207
[TBL] [Abstract][Full Text] [Related]
15. Cumulative Burden of Illness in Veterans With Tardive Dyskinesia and Serious Mental Disorders.
Caroff SN; Leong SH; Roberts C; Berkowitz RM; Campbell EC
J Clin Psychopharmacol; 2020; 40(1):38-45. PubMed ID: 31834084
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
[TBL] [Abstract][Full Text] [Related]
17. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.
Chakos MH; Alvir JM; Woerner MG; Koreen A; Geisler S; Mayerhoff D; Sobel S; Kane JM; Borenstein M; Lieberman JA
Arch Gen Psychiatry; 1996 Apr; 53(4):313-9. PubMed ID: 8634009
[TBL] [Abstract][Full Text] [Related]
18. Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.
Apud JA; Egan MF; Wyatt RJ
Schizophr Res; 2003 Sep; 63(1-2):151-60. PubMed ID: 12892869
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
[TBL] [Abstract][Full Text] [Related]
20. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.
Carbon M; Hsieh CH; Kane JM; Correll CU
J Clin Psychiatry; 2017 Mar; 78(3):e264-e278. PubMed ID: 28146614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
